Pharmaceuticals News and Research

RSS

Cell's reserve fighting force shrinks with age: Study

When the body fights oxidative damage, it calls up a reservist enzyme that protects cells - but only if those cells are relatively young, a study has found.

31 Aug 2011

Positive results from Bionovo's Menerba tolerability trial on menopausal hot flashes

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the positive results from the completion of their tolerability trial of Menerba (MF101) for menopausal hot flashes.

31 Aug 2011

Enrollment commences in Adamis' APC-100 Phase 1/2a clinical prostate study

Adamis Pharmaceuticals Corporation announced today that it enrolled the first patient in its Phase 1/2a clinical prostate study. Adamis' drug, APC-100, will be used to treat men with castrate-resistant prostate cancer.

31 Aug 2011

Insight Pharmaceuticals announces acquisition of MONISTAT business from McNEIL-PPC

Insight Pharmaceuticals, a portfolio company of Swander Pace Capital, announced today that it has acquired the MONISTAT North American brand portfolio from McNEIL-PPC, Inc.

31 Aug 2011

Valeant to acquire Afexa for C$76 million in cash

Valeant Pharmaceuticals International, Inc., announced today that it has agreed to acquire Afexa Life Sciences Inc. for approximately C$76 million.

31 Aug 2011

Alcon chooses Bruker ContourGT-X8 Optical Surface Profiler

Bruker announced today that Alcon Corporation has selected the Bruker ContourGT-X8 Optical Surface Profiler to provide non-destructive, non-contact reference metrology for critical dimensioning and 3D characterization of Alcon's current and next-generation intra-ocular lenses.

From Bruker Nano Surfaces and Metrology 30 Aug 2011

EMD Millipore announces acquisition of Amnis

EMD Millipore, the Life Science division of Merck KGaA of Germany, today announced it has agreed to acquire Seattle-based Amnis Corporation. Amnis designs, manufactures and markets high speed cell imaging instrumentation.

30 Aug 2011

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for RELISTOR Subcutaneous Injection to treat opioid-induced constipation (OIC) in patients with non-cancer pain.

30 Aug 2011

Bristol-Myers Squibb selects ICON as preferred provider for early phase clinical development

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been chosen by Bristol-Myers Squibb Company as a preferred provider for full-service clinical pharmacology and exploratory clinical studies.

30 Aug 2011

DNA sequencing pioneer, two pharmaceutical researchers recognized as ACS 'Heroes of Chemistry'

Two scientists developed a new drug that helped pioneer the era of "personalized medicine" for cancer patients, an approach in which one-size-fits-all drugs yield to medicines customized to the genetic endowment of individual patients. Another scientist invented today's predominant technology for genetic sequencing, deciphering the genetic blueprint in the DNA that makes up the genes of living things.

30 Aug 2011

New chemical compounds show promise against set of protein-folding diseases

Collaborating researchers at Stanford University and The Scripps Research Institute have identified chemical compounds that show promise as potential therapeutics for a set of medical conditions caused by the abnormal clumping together of a protein known as transthyretin.

30 Aug 2011

Student researchers throughout Australia compete for annual award

Student researchers from throughout Australia will compete for state and national titles in the country’s leading competition for life science, biotechnology and bio-engineering students: the 2011 AusBiotech-GSK Student Excellence Awards. Applications are now open for the 2011 awards.

29 Aug 2011

Adimab initiates independent collaborations with Biogen Idec and Novo Nordisk

Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced the initiation of two independent collaborations with Biogen Idec and Novo Nordisk. Over the past two years, Adimab has established collaborations with multiple leading pharmaceutical companies, including: Merck, Roche, Novartis, Pfizer, Eli Lilly, Genentech, Human Genome Sciences, and now Biogen Idec and Novo Nordisk.

29 Aug 2011

Affinium closes $15 million financing round

Affinium Pharmaceuticals announced today the closing of its $15 million financing. Investors participating in the financing include all three of Affinium's Series A investors, SV Life Sciences, Genesis Capital Partners and Forward Ventures, along with the addition of the Ontario Emerging Technologies Fund (OETF) to the syndicate.

29 Aug 2011

UCLA-Harvard medication study highlights 3 types of confusing outcome measures

Studies about medications published in the most influential medical journals are frequently designed in a way that yields misleading or confusing results, new research suggests.

29 Aug 2011

Elsevier, Pharmaron sign multi-year contract for Reaxys

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today that Pharmaron, a premier drug R&D service provider for the pharmaceutical and biotech industry, has signed a multi-year contract with Elsevier, which will provide unlimited Reaxys access to all Pharmaron researchers.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Nurofen mix up with Seroquel schizophrenia drug warns MHRA

British drug regulators have issued a safety alert on Thursday after discovering packs of the over-the-counter painkiller Nurofen Plus containing the anti-psychotic drug Seroquel XL.

26 Aug 2011

Plants stop lethal bleedings after birth in Tanzanian women

Researchers at the Faculty of Pharmaceutical Sciences, University of Copenhagen, have examined a number of plants which are used for illegal abortions in Tanzania. The lab tests show that several of the plants can make the uterus tissue contract and that the plants therefore can be used to stop lethal bleedings after birth. This new knowledge is now to be conveyed in rural Tanzania where access to medicine often is difficult.

26 Aug 2011

NeoStem featured on CBS's Eye on New York City

NeoStem, Inc., an international biopharmaceutical company with a focus on cell-based therapeutic development, today announced that the Company was featured on CBS's Eye on New York City on Wednesday evening, August 24, 2011.

26 Aug 2011